Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals

European Journal of Pharmacology

Volumn 412, Issue 1, 2001, Pages 61-66

  Hayashi, Mikio ^a   Matsuo, Akira ^a   Nakamoto, Hiromitsu ^a   Aisaka, Kazuo ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Anticoagulant; Bleeding time; Factor Xa; JTV 803; Oral administration

Indexed keywords

4 [(2 AMIDINO 1,2,3,4 TETRAHYDRO 7 ISOQUINOLINYLOXY)METHYL] 1 (4 PYRIDINYL) 4 PIPERIDINECARBOXYLIC ACID; 4 [(2 AMIDINO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YLOXY)METHYL] 1 (PYRIDINYL)PIPERIDINE 4 CARBOXYLIC ACID MONOMETHANESULFONATE; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONKEY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; BLEEDING TIME; FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; ISOQUINOLINES; MACACA FASCICULARIS; MALE; PARTIAL THROMBOPLASTIN TIME; PEPTIDE HYDROLASES; PIPECOLIC ACIDS; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES; THROMBOSIS;

EID: 0035910359     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00942-0     Document Type: Article

References (27)

1. In vivo models of arterial thrombosis and thrombolysis
2. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases
3. Anticoagulant therapy
4. Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: Probable role of the complex in the amplification of blood coagulation
5. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis
6. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: Prevention by a maintenance infusion
7. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor
8. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats
9. Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs
10. Importance of photo activation of rose bengal for platelet activation in experimental models of photochemically induced thrombosis
11. Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide
12. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model
13. Properties of the factor Xa binding site on human platelets
14. The contribution of bovine factor V and factor Va to the activity of prothrombinase
15. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis
16. Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa
17. Heparin 1986. Indications and effective use
18. Control mechanisms in thrombin generation
19. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay
20. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits
21. Vessel wall injury and arterial thrombosis induced by a photochemical reaction
22. Flow and the inhibition of prothrombinase by antithrombin III and heparin
23. DX-9065a, an orally active factor Xa inhibitor, dose not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model
24. Protection of factor Xa from neutralization by the heparin-antithrombin complex
25. Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors
26. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis
27. Human platelet factor V is crosslinked to actin by FXIIIa during platelet activation by thrombin